Twitter Facebook LinkedIn
Center for Global Research Data

Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial

Lead Investigator: Alana Rojewski, Medical University of South Carolina
Title of Proposal Research: Smoking Cessation Pharmacotherapy Efficacy in Comorbid Medical Populations: Secondary Analysis of the EAGLES Randomized Clinical Trial
Vivli Data Request: 6836
Funding Source: Dr. Rojewski (lead researcher) is funded by a career development grant from the National Cancer Institute that supports her efforts, including projects such as the present proposal.
Potential Conflicts of Interest: Dr. Toll has consulted to Pfizer for an advisory board on e-cigarettes and testifies as an expert witness on behalf of plaintiffs who filed litigation against the tobacco industry.

Summary of the Proposed Research:

The objective of this study is to compare medication efficacy in participants who have medical and psychiatric conditions and smoke cigarettes in the EAGLES trial. Nicotine replacement therapy and varenicline may work differently in comorbid populations in terms of ability to quit smoking, particularly as the number of comorbidities increases. We will use statistical analyses to compare these groups. Exploring how well the medications work for medically complex patients has important implications for tobacco treatment.

Requested Studies:

Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders (EAGLES)
Sponsor: Pfizer Inc.
Study ID: NCT01456936
Sponsor ID: NCT01456936